
Biotech firms favor dual IPO and acquisition strategies amid selective investor climate and Big Pharma pipeline needs.
Biotech companies are increasingly adopting a dual-track approach by preparing for IPOs while also engaging with potential acquirers, as investors have become more selective since the pandemic boom. Big Pharma is actively seeking to replenish drug pi...

